Eli Lilly PET Drug Misbranded by Misleading Imagery, FDA Says

Washington Drug Letter
Eli Lilly has misbranded its radioactive PET drug Amyvid, approved for reviewing displays of brain scans using a black-and-white scale, by featuring a multi-colored brain image on a webpage advertisement and other promotional materials for the product, according to an FDA untitled letter.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00